original ) (raw )Enhanced 2-deoxy-2- (18F) fluoro-D-glucose (FDG) Uptake on PET-CT Due to a Benign Condition and Hodgkin’s Lymphoma
Arif Sheikh
Journal of Nuclear Medicine & Radiation Therapy, 2013
View PDFchevron_right
Role of whole-body [18 F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of …
Gianni Bisi , U. Vitolo
La Radiologia …, 2008
View PDFchevron_right
2-Deoxy-2-[F-18]Fluoro-D-Glucose Imaging with Positron Emission Tomography for Initial Staging of Hodgkin's Disease and Lymphoma
John Greer
Molecular Imaging & Biology, 2002
View PDFchevron_right
Positron emission tomography with 2-[18F]-Fluoro-2-Deoxy-D-Glucose for initial staging of hodgkin lymphoma: a single center experience in Brazil
Juliano Cerci
Clinics, 2009
View PDFchevron_right
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials
Lalitha Shankar
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006
View PDFchevron_right
Whole-Body Positron Emission Tomography Using18F-Fluorodeoxyglucose for Posttreatment Evaluation in Hodgkin’s Disease and Non-Hodgkin’s Lymphoma Has Higher Diagnostic and Prognostic Value Than Classical Computed Tomography Scan Imaging
Patrick Paulus
Blood, 1999
View PDFchevron_right
Kostakoglu, L. & Goldsmith, S. J. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J. Nucl. Med. 44, 224-239
Lale Kostakoglu
Journal of Nuclear Medicine
View PDFchevron_right
Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease
T. Sattar
Annals of Oncology, 2004
View PDFchevron_right
Quantitative assessment of 18F-FDG PET in patients with Hodgkin lymphoma
Conrad-Amadeus Voltin
Nuclear Medicine Communications, 2018
View PDFchevron_right
Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose
Heikki Minn
Blood, 1995
View PDFchevron_right
Malignancies with Low Fluorodeoxyglucose Uptake at PET/CT: Pitfalls and Prognostic Importance:Resident and Fellow Education Feature
Miguel Hernandez Pampaloni
RadioGraphics, 2016
View PDFchevron_right
18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma
Lale Kostakoglu
2000
View PDFchevron_right
The role of FDG PET / CT in lymphomas
Gabriella Dabasi
2015
View PDFchevron_right
[18F]Fluorodeoxyglucose-PET/Computed Tomography, PET, and Magnetic Resonance Imaging
Lina Mehta
PET Clinics, 2012
View PDFchevron_right
Frequent Impact of [ 18 F]Fluorodeoxyglucose Positron Emission Tomography on the Staging and Management of Patients with Indolent Non-Hodgkin's Lymphoma
andrew wirth
Clinical Lymphoma & Myeloma, 2003
View PDFchevron_right
18FDG PET in oncology: The best and the worst (Review)
Tarik-Zine Belhocine
International Journal of Oncology, 2006
View PDFchevron_right
Physiology and Pathophysiology of Incidental Findings Detected on FDG-PET Scintigraphy
lionel zuckier
Seminars in Nuclear Medicine, 2010
View PDFchevron_right
Metabolic Test with FLUORINE-18-FLUORODEOXYGLUCOSE in Staging and Detection of Residual Tumor or Recurrence in Hodgkin Lymphoma
Claudio Meneghetti
Clinics, 2007
View PDFchevron_right
[Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment]
Simone Maurea
La radiologia medica
View PDFchevron_right
Cohade C. Impact of intravenous insulin on 18F-FDG PET in diabetic cancer patients. J Nucl Med 2009;50:178–83
Luc Boucher
2015
View PDFchevron_right
Current role of FDG PET/CT in lymphoma
Lale Kostakoglu
European Journal of Nuclear Medicine and Molecular Imaging, 2014
View PDFchevron_right
Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma
Jamshid Maddahi
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1997
View PDFchevron_right
Staging, Response to Therapy, and Restaging of Lymphomas with 18F-FDG PET
Jaime de la Garza Salazar , Jaime Garza
Archives of Medical Research, 2008
View PDFchevron_right
Clinical Sciences Metabolic Test with FLUORINE-18- Fluorodeoxyglucose in Staging and Detection of Residual Tumor or Recurrence in Hodgkin Lymphoma
Anna Alice
2006
View PDFchevron_right
Prognostic value of the maximum standardized uptake value of staging FDG-PET/CT in Hodgkin lymphoma
Stephen Schuster
Journal of Clinical Oncology, 2014
View PDFchevron_right
FDG-PET in the clinical management of Hodgkin lymphoma
Lena Specht
Critical Reviews in Oncology/Hematology, 2004
View PDFchevron_right
Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006;47:885–95
Scott Holbrook
2015
View PDFchevron_right
FDG-PET imaging in hematological malignancies
Laia Valls
Blood Reviews, 2016
View PDFchevron_right
18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging
David Sibon
European Journal of Nuclear Medicine and Molecular Imaging, 2010
View PDFchevron_right